Skip to content

13F-HR filed by Sarissa Capital Management LP

Sarissa Capital Management LP filed this 13F-HR for the quarter ended 2026-06-30, filed 2026-08-14, with 10 holding rows worth $177,878,251.

Accession
0000899140-26-000879
Filed
2026-08-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q2 2026

A holdings report, 10 entries on the cover page, a total value of $177,878,251 stated on the cover page (in dollars after the unit check, H1), rows summing to $177,878,251 with VALUE read as dollars as filed, 13F file number 028-15935. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
INNOVIVA INC45781M101COM1,890,604$42,935,617dollars as filed
IRONWOOD PHARMACEUTICALS INC46333X108COMMON STOCK9,188,635$38,684,153dollars as filed
AMARIN CORP PLC023111404SPONSORED ADR1,673,395$26,673,916dollars as filed
NEUROCRINE BIOSCIENCES INC64125C109COM116,533$19,639,889dollars as filed
CYTOKINETICS INC23282W605COM NEW228,623$19,476,393dollars as filed
LANTHEUS HLDGS INC516544103COM166,919$18,517,994dollars as filed
BIOHAVEN LTDG1110E107COM582,312$8,664,803dollars as filed
REGENERON PHARMACEUTICALS COM75886F107Stock4,190$2,612,633dollars as filed
VOR BIOPHARMA INC929033207COMMON STOCK25,399$467,596dollars as filed
BIOGEN INC COM09062X103Stock950$205,257dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000899140-26-000879this filing2026-08-14acceptance time not in the bulk data set